Also, as noted previously for both human and mouse melanoma cells (Misek et al., 2020; Foda and Neubig, 2023), the Vem-resistant cells were more sensitive to single-drug treatment with the pirin-binding MRTF-pathway inhibitor (CCG compound) than were the sensitive cells. The gene discussed is PIR; the disease is melanoma.